Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Launched by FRIEDREICH'S ATAXIA RESEARCH ALLIANCE · Aug 23, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study is a research project aimed at understanding the progression of Friedreich ataxia, a genetic condition that affects movement and coordination. This study is taking place in multiple locations around the world and is designed to gather important information that can help in developing new treatments for this condition. Researchers are looking for participants of all ages, both males and females, who have been genetically confirmed to have Friedreich ataxia.
If you or a loved one is interested in participating, you’ll need to provide written consent, and if the participant is a minor, a parent or legal guardian will need to sign as well. Participants can expect to take part in various assessments over time, helping researchers learn more about how the disease affects individuals. This study is currently recruiting participants, but some people may not be eligible if they have other serious health issues or cannot provide consent. Your involvement could play a crucial role in advancing our understanding and treatment of Friedreich ataxia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Both males and females of any age
- • 2. Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed diagnosis of Friedreich ataxia
- • 3. Written informed consent provided
- • 1. Informed consent must be obtained for all participants
- • 2. For underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable)
- • 3. Persons who are not legally competent require the informed consent of their legally authorized representative
- Exclusion Criteria:
- • 4. Unable or unwilling to provide informed consent
- • 5. Acute or ongoing medical or other conditions that would interfere with the conduct and assessments of the study
- • 6. For any reason in the opinion of the investigator, participant would be unlikely or unable to comply with study protocol requirements.
About Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance (FARA) is a non-profit organization dedicated to advancing research and developing treatments for Friedreich's ataxia (FA), a rare genetic disorder that primarily affects movement and coordination. Established to foster collaboration among researchers, clinicians, and patient communities, FARA plays a pivotal role in funding innovative research initiatives, facilitating clinical trials, and promoting awareness of FA. Through strategic partnerships and advocacy, FARA aims to accelerate the discovery of effective therapies and improve the quality of life for individuals affected by this debilitating condition.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Memphis, Tennessee, United States
Denver, Colorado, United States
Toronto, Ontario, Canada
Auckland, , New Zealand
Milan, , Italy
Campinas, , Brazil
Innsbruck, , Austria
Aachen, , Germany
Bonn, , Germany
Tübingen, , Germany
Madrid, , Spain
Gainesville, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Columbus, Ohio, United States
Parkville, Victoria, Australia
Los Angeles, California, United States
Iowa City, Iowa, United States
Montréal, Quebec, Canada
Bruxelles, , Belgium
Praha, , Czechia
Paris, , France
Strasbourg, , France
Munich, , Germany
Athens, , Greece
Dublin, , Ireland
Roma, , Italy
Barcelona, , Spain
London, , United Kingdom
Paris, , France
New Delhi, Nct, India
Conegliano, , Italy
Bonn, , Germany
Montreal, Quebec, Canada
Nijmegen, , Netherlands
Memphis, Tennessee, United States
Patients applied
Trial Officials
David Lynch, MD
Principal Investigator
Children's Hospital of Philadelphia
Jorg B Schulz, Prof
Principal Investigator
University Hospital, Aachen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported